Palvella Therapeutics Prices Upsized Public Offering

Biopharmaceutical company raises $200 million to advance rare skin disease treatments

Published on Feb. 26, 2026

Got story updates? Submit your updates here. ›

Palvella Therapeutics, a clinical-stage biopharmaceutical company focused on developing therapies for rare skin diseases, announced the pricing of its upsized public offering of 1,600,000 shares of common stock at $125.00 per share. The offering is expected to raise $200 million in gross proceeds for the company, which it plans to use to support the development of its QTORIN rapamycin and QTORIN pitavastatin programs.

Why it matters

Palvella's pipeline of rare disease treatments aims to address unmet medical needs, as there are currently no FDA-approved therapies for the conditions the company is targeting. The successful completion of this public offering will provide Palvella with the necessary capital to advance its clinical programs and potentially bring new treatment options to patients suffering from serious, rare skin diseases.

The details

The public offering was upsized from the original plan, with Palvella granting the underwriters a 30-day option to purchase up to an additional 240,000 shares. The offering is expected to close on or about February 27, 2026, subject to customary closing conditions. Palvella intends to use the net proceeds to support the development of its QTORIN rapamycin and QTORIN pitavastatin programs, as well as for working capital and other general corporate purposes.

  • The public offering is expected to close on or about February 27, 2026.

The players

Palvella Therapeutics, Inc.

A clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations.

TD Cowen

One of the joint bookrunning managers for the public offering.

Cantor

One of the joint bookrunning managers for the public offering.

Stifel

One of the joint bookrunning managers for the public offering.

Mizuho

One of the joint bookrunning managers for the public offering.

Got photos? Submit your photos here. ›

What’s next

The offering is expected to close on or about February 27, 2026, subject to the satisfaction of customary closing conditions.

The takeaway

Palvella's successful public offering will provide the necessary funding to advance its pipeline of rare skin disease treatments, potentially bringing new therapeutic options to patients in need of FDA-approved therapies.